Comparison 1. Children with fever and neutropenia: lipid preparation of amphotericin B versus conventional amphotericin B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all cause)	1	95	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.17, 3.11]
2 Mortality (related to fungal infection)	1	95	Risk Ratio (M‐H, Random, 95% CI)	0.20 [0.01, 3.98]
3 Complete resolution of fungal infection	1	5	Risk Ratio (M‐H, Random, 95% CI)	1.5 [0.18, 12.46]
4 Partial resolution of fungal infection	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Resolution of fever in suspected fungal infection	2	297	Risk Ratio (M‐H, Random, 95% CI)	1.23 [1.00, 1.52]
6 Progression of disease requiring change / addition of an antifungal agent	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Breakthrough fungal infection requiring change / addition of an antifungal agent	3	345	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.24, 1.84]
8 Any clinically significant adverse reactions attributed to the antifungal agent resulting in discontinuation, dose reduction or change in therapy	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
9 Any clinically significant adverse reactions attributed to the antifungal agent (total)	2	299	Risk Ratio (M‐H, Random, 95% CI)	0.49 [0.21, 1.17]
10 Nephrotoxicity	4	371	Risk Ratio (M‐H, Random, 95% CI)	0.43 [0.21, 0.90]
11 Hypokalaemia	3	345	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.45, 1.14]
12 Hepatotoxicity	3	345	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.74, 1.71]
13 Infusion‐related reactions	2	284	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.59, 1.38]
13.1 Fever ‐ Liposomal AmB vs. Conventional Amphotericin B	1	96	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.86, 1.11]
13.2 Fever ‐ ABCD vs. Conventional Amphotericin B	1	46	Risk Ratio (M‐H, Random, 95% CI)	0.94 [0.69, 1.27]
13.3 Chills ‐ Liposomal AmB vs. Conventional Amphotericin B	1	96	Risk Ratio (M‐H, Random, 95% CI)	0.37 [0.21, 0.64]
13.4 Chills ‐ ABCD vs. Conventional Amphotericin B	1	46	Risk Ratio (M‐H, Random, 95% CI)	1.76 [1.09, 2.85]
14 Haematological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
15 Neurological disturbances	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Gastrointesitnal toxicity	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
17 Length of Stay	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
18 Quality of Life	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
19 Cost	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]